Skip to main content
MMedVellum
MCQsExamsAtlas
DashboardPricing
MMedVellum

The exam atlas that feels like a flagship product — evidence-graded topics and exam tools for MBBS and fellowship preparation. Built to scale to fifty specialties. Educational content only — not medical advice.

llms.txt·psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Clinical Atlas Prestige · Evidence-first

Psych MEQs / SAQsGeneral adult psychiatry — early psychosis pathway

Psych MEQs / SAQs · General adult psychiatry — early psychosis pathway

First-episode psychosis pathway — assessment to recovery (MEQ)

FRANZCP-style MEQ on the first-episode psychosis pathway: DUP, organic exclusion, low-dose antipsychotic initiation, OPUS/RAISE multi-element care, maintenance duration and cannabis secondary prevention.

20 marks20 min
On this page & tools

Target exams

FRANZCPMRCPsychABPNMD-DNB

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
A 19-year-old university student is brought by his parents after 5 months of social withdrawal and 8 weeks of believing classmates are tracking him through his phone. He hears a third-person commentary. He smokes high-THC cannabis most evenings. Observations and bedside glucose are normal; he is alert and afebrile. Insight is partial. (i) Define FEP and calculate the clinical importance of DUP in this case. (ii) Outline organic exclusion and baseline investigations before antipsychotics. (iii) Give a named first-line oral antipsychotic with starting dose, monitoring and trial length. (iv) Describe the multi-element early intervention package and the evidence base (name at least two landmark programmes or syntheses). (v) Counsel on maintenance duration after remission and on cannabis. (20 marks)

Model answer

Reveal model answer

(i) FEP and DUP. First-episode psychosis is a clinical/service pathway for a first clear psychotic presentation, not a single DSM/ICD final label. Working diagnosis: first-episode schizophrenia-spectrum psychosis (duration still may sit in schizophreniform range depending on total continuous signs). DUP here is at least about 8 weeks of frank psychosis (phone tracking, commentary) and longer if prodromal withdrawal is counted under DUI definitions — already clinically important because longer DUP associates with poorer outcomes and should be stopped by starting adequate treatment now.[2]

(ii) Organic exclusion and baseline tests. History for fever, seizure, head injury, neurological symptoms; physical examination; observations already reassuring. Baseline before antipsychotic: BMI/weight, BP, glucose or HbA1c, lipids, FBC, U&E, LFT, ECG QTc, pregnancy test if applicable, substance timeline. Image/EEG/autoimmune pathway if red flags later emerge. Urine drug screen supports but does not exclude primary illness.[1]

(iii) Antipsychotic plan. Example: aripiprazole 10 mg orally daily after baselines, with education about akathisia. Review within days; trial about 4–6 weeks at therapeutic dose with adherence support. Alternatives: risperidone 1–2 mg titrating carefully, or olanzapine 5–10 mg if sedation needed but metabolic risk disclosed. Avoid high first-episode doses without justification.[1]

(iv) Multi-element EIS. Refer to early intervention / coordinated specialty care: low-dose medication, family psychoeducation, case management, CBTp access, cannabis counselling, vocational/education support (IPS). Evidence: RAISE-ETP (NAVIGATE superior to usual care at 2 years), OPUS intensive early intervention benefits, and Correll meta-analysis favouring EIS versus treatment as usual.[1][5]

(v) Maintenance and cannabis. After remission, counsel that stopping medication early carries high recurrence risk; plan continued antipsychotic treatment for a guided period commonly framed as at least 1–2 years, with any later taper supervised and paired with an early-warning plan.[3] Cannabis: frequency and high-THC use worsen course; continued use after onset associates with earlier relapse — motivational cessation support is core secondary prevention, integrated with psychosis care.[4]

Common errors

  • Equating FEP with definite lifelong schizophrenia on day one.
  • Starting antipsychotics without metabolic/ECG baseline.
  • Omitting family intervention and EIS multi-element modules.
  • Advising unsupervised stop after a few well weeks.
  • Ignoring cannabis or withholding treatment until abstinence.
  • Inventing Mental Health Act section numbers for the wrong jurisdiction. [1]

Examiner notes

Full marks require DUP reasoning, organic/baseline checklist, named drug with dose and monitoring, named EIS evidence (OPUS/RAISE/meta-analysis), maintenance duration with Zipursky-style risk framing, and cannabis secondary prevention. Vague "start an atypical and refer" fails. [1][5]

References

  1. [1]Kane JM, Robinson DG, Schooler NR, et al. Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2-Year Outcomes From the NIMH RAISE Early Treatment Program Am J Psychiatry, 2016.PMID 26481174
  2. [2]Marshall M, Lewis S, Lockwood A, et al. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review Arch Gen Psychiatry, 2005.PMID 16143729
  3. [3]Zipursky RB, Menezes NM, Streiner DL Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review Schizophr Res, 2014.PMID 23972821
  4. [4]Schoeler T, Petros N, Di Forti M, et al. Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study Lancet Psychiatry, 2016.PMID 27567467
  5. [5]Correll CU, Galling B, Pawar A, et al. Comparison of Early Intervention Services vs Treatment as Usual for Early-Phase Psychosis: A Systematic Review, Meta-analysis, and Meta-regression JAMA Psychiatry, 2018.PMID 29800949